SINGAPORE, Sept. 25,
2023 /PRNewswire/ -- CytoMed Therapeutics
Limited (NASDAQ: GDTC) ("CytoMed" or "Company"), a Singapore-based biopharmaceutical company
focused on harnessing its proprietary technologies to develop novel
donor-derived cell-based allogeneic immunotherapies for the
treatment of various cancers, today announced that its exclusively
licensed induced pluripotent stem cell (iPSC)-based technology has
been granted a patent by the China National Intellectual Property
Administration (CNIPA).
"We're thrilled to strengthen our existing suite of patents,"
said Peter Choo, Chairman of
CytoMed. "Now this novel iPSC-based technology has been granted
patent in China and Japan (where the iPSC technology was pioneered
in 2006). Such progress further expands the Company's current
patent portfolio to three countries, consisting of and including
patents granted in the US and China for our licensed allogeneic chimeric
antigen receptor gamma delta T cell (CAR-γδ T cell) technology
which is expected to start phase I clinical trial in Singapore soon."
For cancer treatment, immune cells such as γδ T cells and
natural killer (NK) cells are invaluable therapeutic cells due to
their ability to express an array of built-in receptors that
recognize stress-induced cancer antigens naturally.
By combining the iPSC technology and directed differentiation,
CytoMed can generate a novel type of synthetic hybrid immune cells,
γδ NKT cells, that express cancer recognition receptors of both γδ
T cells and NK cells to recognize a wide range of cancers without
genetic modification or use of viral vectors. As an allogeneic cell
source, the Company's iPSC-derived γδ NKT cells may potentially
become an "off-the-shelf" cell therapy that is applicable to a
large pool of patients.
The patent titled "Methods and Kits for Generating Mimetic
Innate Immune Cells from Pluripotent Stem Cells" with Patent No.
ZL201880022790.X, published as CN 110691844
B, covers technologies to derive novel synthetic γδ NKT
cells for the treatment of various types of cancers including
hematological malignancies and solid tumors. This asset is
currently under preclinical development. The Company holds an
exclusive, worldwide license to use this patent pursuant to the
Licence Agreement dated June 1, 2018,
which was filed with the Securities and Exchange Commission as an
exhibit to the registration statement on Form F-1 (File No.:
333-268456) on March 30, 2023.
About CytoMed Therapeutics Limited (CytoMed)
Incorporated in 2018, CytoMed was spun off from the Agency for
Science, Technology and Research (A*STAR), Singapore's leading research and development
agency in the public sector. It is a biopharmaceutical company
focused on harnessing its licensed proprietary technologies to
create novel cell-based immunotherapies for the treatment of human
cancers. The development of novel technologies has been inspired by
the clinical success of existing CAR-T therapies in treating
hematological malignancies, as well as the current clinical
limitations and commercial challenges in extrapolating the CAR-T
principle into treatment of solid tumors. For more information,
please visit www.cytomed.sg and follow us on Twitter @CytomedSG,on
LinkedIn, and Facebook
Forward Look Statements
This press release contains forward-looking statements as
defined by the Private Securities Litigation Reform Act of 1995.
Forward-looking statements include statements concerning plans,
objectives, goals, strategies, future events or performance, and
underlying assumptions and other statements that are other than
statements of historical facts. When the Company uses words such as
"may, "will, "intend," "should," "believe," "expect," "anticipate,"
"project," "estimate" or similar expressions that do not relate
solely to historical matters, it is making forward-looking
statements. Forward-looking statements are not guarantees of future
performance and involve risks and uncertainties that may cause the
actual results to differ materially from the Company's expectations
discussed in the forward-looking statements. These statements are
subject to uncertainties and risks including, but not limited to,
the following: the Company's plans to develop and
commercialize its product candidates; the initiation, timing,
progress and results of the Company's current and future
pre-clinical studies and clinical trials and the Company's R&D
programs; the Company's expectations regarding the impact of the
ongoing COVID-19 pandemic on its business, the Company's industry
and the economy; the Company's estimates regarding expenses, future
revenue, capital requirements and needs for additional financing;
the Company's ability to successfully acquire or obtain licenses
for additional product candidates on reasonable terms; the
Company's ability to establish and maintain collaborations and/or
obtain additional funding and assumptions underlying or related to
any of the foregoing and other risks contained in reports filed by
the Company with the SEC. For these reasons, among others,
investors are cautioned not to place undue reliance upon any
forward-looking statements in this press release. Additional
factors are discussed in the Company's filings with the SEC, which
are available for review at www.sec.gov. The Company undertakes no
obligation to publicly revise these forward–looking statements to
reflect events or circumstances that arise after the date
hereof.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/chinese-patent-granted-for-cytomed-therapeutics-licensed-ipsc-based-technology-301936668.html
SOURCE CytoMed Therapeutics Limited
